

*Citation for published version:*

Effinger, A, O'Driscoll, CM, McAllister, M & Fotaki, N 2018, In vitro and In silico ADME prediction. in A Talevi & PA Quiroga (eds), *ADME Processes in Pharmaceutical Sciences: Dosage, Design, and Pharmacotherapy Success*. Springer.

*Publication date:*  
2018

*Document Version*  
Peer reviewed version

[Link to publication](#)

**University of Bath**

## **Alternative formats**

If you require this document in an alternative format, please contact:  
[openaccess@bath.ac.uk](mailto:openaccess@bath.ac.uk)

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## Chapter 13

### *In vitro* and *in silico* and ADME prediction

Angela Effinger<sup>1</sup>, Caitriona M. O'Driscoll<sup>2</sup>, Mark McAllister<sup>3</sup>, Nikoletta Fotaki<sup>1\*</sup>

|          |   |                                     |
|----------|---|-------------------------------------|
| <b>1</b> | <b>Introduction.....</b>                                  | <b>Error! Bookmark not defined.</b> |
| <b>2</b> | <b>Absorption .....</b>                                   | <b>Error! Bookmark not defined.</b> |
| 2.1      | <i>In vitro</i> methods.....                              | <b>Error! Bookmark not defined.</b> |
| 2.1.1    | Solubility.....   | <b>Error! Bookmark not defined.</b> |
| 2.1.2    | <i>In vitro</i> release and dissolution testing .....     | <b>Error! Bookmark not defined.</b> |
| 2.1.3    | Permeability .....  | <b>Error! Bookmark not defined.</b> |
| 2.1.4    | Active transport.....                                     | <b>Error! Bookmark not defined.</b> |
| 2.1.5    | Gut wall metabolism .....                                 | <b>Error! Bookmark not defined.</b> |
| 2.2      | <i>In silico</i> methods .....                            | <b>Error! Bookmark not defined.</b> |
| 2.2.1    | Solubility.....   | <b>Error! Bookmark not defined.</b> |
| 2.2.2    | Drug release and dissolution.....                         | <b>Error! Bookmark not defined.</b> |
| 2.2.3    | Permeability .....  | <b>Error! Bookmark not defined.</b> |
| 2.2.4    | Active transport.....                                     | <b>Error! Bookmark not defined.</b> |
| 2.2.5    | Gut wall metabolism .....                                 | <b>Error! Bookmark not defined.</b> |
| 2.2.6    | Dynamic transit models.....                               | <b>Error! Bookmark not defined.</b> |
| <b>3</b> | <b>Distribution.....</b>                                  | <b>Error! Bookmark not defined.</b> |
| 3.1      | <i>In vitro</i> methods.....                              | <b>Error! Bookmark not defined.</b> |
| 3.2      | <i>In silico</i> methods .....                            | <b>Error! Bookmark not defined.</b> |
| <b>4</b> | <b>Metabolism.....</b>                                    | <b>Error! Bookmark not defined.</b> |
| 4.1      | <i>In vitro</i> methods.....                              | <b>Error! Bookmark not defined.</b> |
| 4.2      | <i>In silico</i> methods .....                            | <b>Error! Bookmark not defined.</b> |
| <b>5</b> | <b>Excretion.....</b>                                     | <b>Error! Bookmark not defined.</b> |
| 5.1      | <i>In vitro</i> methods.....                              | <b>Error! Bookmark not defined.</b> |
| 5.2      | <i>In silico</i> methods .....                            | <b>Error! Bookmark not defined.</b> |
| <b>6</b> | <b>Physiologically-based pharmacokinetic models .....</b> | <b>Error! Bookmark not defined.</b> |
| <b>7</b> | <b>Conclusion .....</b>                                   | <b>Error! Bookmark not defined.</b> |

---

**Nikoletta Fotaki<sup>1\*</sup>**

**Department of Pharmacy and Pharmacology, University of Bath**

**Claverton Down**

**Bath, BA2 7AY**

**United Kingdom**

**Tel. +44 1225 386728**

**Fax: +44 1225 386114**

**E-mail: [n.fotaki@bath.ac.uk](mailto:n.fotaki@bath.ac.uk)**

**Angela Effinger<sup>1</sup>**

**<sup>1</sup> Department of Pharmacy and Pharmacology, University of Bath, Bath, UK**

**Email: [a.effinger@bath.ac.uk](mailto:a.effinger@bath.ac.uk)**

**Caitriona M. O'Driscoll<sup>2</sup>**

**<sup>2</sup> School of Pharmacy, University College Cork, Cork, Ireland**

**[Email: caitriona.odriscoll@ucc.ie](mailto:caitriona.odriscoll@ucc.ie)**

**Mark McAllister<sup>3</sup>**

**<sup>3</sup> Pfizer Drug Product Design, Sandwich, UK**

**Email: [Mark.McAllister@pfizer.com](mailto:Mark.McAllister@pfizer.com)**

### **Abstract (only online version)**

Pharmacokinetic issues have been identified as a major cause for the attrition of new chemical entities in drug discovery. High development costs and time investments are associated with the discovery of such issues during clinical drug development. To overcome this problem, various in vitro and in silico ADME (Absorption, Distribution, Metabolism, Excretion) tools have been developed to predict drug pharmacokinetics using only a minimal amount of experimental data. Selecting the most appropriate option(s) from this broad range of in vitro and in silico

ADME tools is challenging for drug discovery scientists as it requires consideration of a number of factors including the stage of the discovery process, any data already generated for a lead molecule or series and an awareness of the limitations and advantages of each ADME tool. ADME parameters, obtained through experimental approaches and/or *in silico* prediction, are also essential inputs to physiologically-based pharmacokinetic models for the prediction of *in vivo* pharmacokinetics. Available *in vitro* and *in silico* ADME tools are presented and assessed in the following book chapter.

**Key words (only online version)**

*In vitro* methods,  
*In silico* methods,  
 Absorption,  
 Distribution,  
 Metabolism,  
 Excretion,  
 Physiologically-based pharmacokinetic modelling

## 1. Introduction

A study in 1997 showed that 39% of new chemical entities failed in clinical drug development due to issues related to pharmacokinetics (Kennedy 1997). This finding underlined the need for the development of tools suitable to identify compounds with a poor bioavailability at an early stage in the drug discovery process. In the last decades, a large number of *in vitro* and *in silico* tools for ADME prediction has been developed that contributed to the reduction of the drug attrition rate due to poor pharmacokinetic properties to 10% in 2000 (Kola and Landis 2004). Especially, the prediction of cytochrome P450 (CYP) related metabolism added to this improvement. ADME prediction for drug candidates using *in vitro* and *in silico* tools, helps in the selection of lead compounds before reaching clinical trials. In turn, unsuccessful drug candidates can be identified at an earlier stage resulting in the saving of time and costs. The knowledge of advantages and limitations of each ADME prediction tool are key to select the appropriate tool and to build confidence in the prediction. Considering drug absorption, solubility and dissolution studies are especially important for poorly soluble drugs while for other compounds absorption may be limited by intestinal membrane permeability. Drug

distribution can have implications on the duration of the drug effect and be associated with a risk of not reaching therapeutic concentrations *in vivo*, especially for lipophilic drugs. The use of *in vitro* and *in silico* tools assessing plasma protein binding, partitioning into red blood cells and distribution into peripheral tissues helps to identify those issues. Drug metabolism by metabolic enzymes influences the clearance profile and is often a source of interindividual pharmacokinetic variability or Drug-Drug interactions. *In vitro* and *in silico* predictions of drug metabolism should consider the enzymatic reaction as well as the relevant enzymatic expression in the respective tissue. Drug exposure can also be limited by drug excretion. Therefore, *in vitro* and *in silico* tools are available for the complex processes of biliary and renal excretion. While the consideration of each of the previous ADME processes separately helps to identify issue related to one process, their mutual interaction can negate or improve the drug's pharmacokinetic profile. Physiologically-based pharmacokinetic (PBPK) models take into account all ADME processes together by integration of various experimental results, and *in silico* predictions of unknown parameters and *in vivo* performance can be made.

#### Overview ends

## 2. Absorption

Drug absorption after oral administration is a very complex process influenced by drug properties, formulation-dependent factors and physiological conditions. Drug absorption includes several underlying processes e.g., release and/or dissolution of the drug from the pharmaceutical formulation in the gastrointestinal fluids and permeation of the dissolved drug through the gastrointestinal membrane. Therefore, determination of the rate-limiting process governing the absorption of the investigated drug based on its physicochemical properties is essential.

The Biopharmaceutics Classification System (BCS), introduced in 1995 by Amidon et al. (1995), aimed to correlate *in vitro* drug dissolution with *in vivo* bioavailability. Drugs are classified based on three dimensionless parameters determining their absorption (dose number, dissolution number and absorption number) and their underlying drug properties (solubility and permeability). Four different BCS classes are defined: BCS class 1 includes compounds with high solubility and high permeability for which gastric emptying (for when drug dissolution is very rapid) or drug dissolution are the rate limiting step to drug absorption. BCS class 2 drugs have a

low solubility and a high permeability presenting solubility or dissolution rate limited absorption. BCS class 3 contains high solubility and low permeability compounds for which the rate limiting step to drug absorption is permeability. BCS class 4 includes low solubility and low permeability compounds which are usually challenging for oral drug delivery. Once a compound is classified according to the BCS, formulation development can be guided. For example, if the solubility of a compound is problematic, subsequent efforts in formulation development with e.g. enabling formulations may be required.

Several “rule of thumb” approaches have been introduced to categorise new chemical entities according to characteristics which increase their likeliness to be adequately absorbed *in vivo*. The most popular method to identify compounds at risk of poor absorption and permeation was developed based on an analysis of the World Drug Index and is called Lipinski’s “rule of five”. The rule implies that drugs with >5 hydrogen bond donors, a molecular weight >500 Da, an octanol-water partition coefficient (log P) >5 and >10 hydrogen bond acceptors have an increased risk for poor absorption (Lipinski et al. 2001). An exception of this rule are drug classes that are substrates for biological transporters. Another analysis by Veber et al. (2002) used oral bioavailability data of over 1000 drugs in rats and identified that drugs with ≤10 rotatable bonds and a polar surface area ≤140 Å<sup>2</sup> (or 12 or fewer H-bond donors and acceptors) are likely to have a good oral bioavailability. The bioavailability score is another approach stating that the predominant charge at biological pH determines the properties that are important for a compound’s bioavailability (Martin 2005). The important parameter for anions is the polar surface area, while for neutral, zwitterionic or cationic compounds the previously described Lipinski’s rule of five is more predictive. Additional strategies aim to identify drug-like molecules that are also expected to meet ADME profiles using simple structural rules or neural network approaches (Muegge et al. 2001).

## **2.1 *In vitro* methods**

### **2.1.1 Solubility**

Drug solubility can be a limiting factor in drug absorption and its importance is highlighted by the fact that 75% drug development candidates are poorly soluble and belong to BCS class 2 or 4 (Di et al. 2009). In early development, high throughput methods are used to determine the solubility of a large number of compounds.

These methods typically include a concentrated stock solution of the investigated drug in DMSO which is either directly added to a buffer (often pH 6.5 or 7.4) or evaporated and subsequently a buffer is added to the remaining material to reduce the effect of DMSO on solubility. The solution can be analysed by different methods including light scattering, turbidimetry, LC-UV or LC-MS. The drug concentration at which the first induced precipitate appears in a solution is called kinetic solubility. A 'semi-equilibrium' solubility refers to the solution being incubated for approximately one day followed by its filtration and the determination of drug concentration (Di et al. 2012a). While the latter method allows some time for equilibration between solid drug and solution, supersaturation is a frequent problem for kinetic solubility measurements. Additionally, the evaporation of DMSO can leave the drug in an energetically higher state (amorphous form) possibly resulting in a higher solubility. Consequently, high throughput methods present the "best case scenario" of drug solubility (Di et al. 2012a).

Equilibrium (thermodynamic) solubility refers to the concentration of the saturated solution in equilibrium with the thermodynamically stable polymorph (Bergstrom et al. 2014). Measurements of equilibrium solubility are performed with the shake flask method in later phases of drug development when crystalline drug material becomes available. The characterisation of the solid form by e.g. polarized light microscopy and powder X-ray diffraction provides information about potential solid form changes.

At this stage, apart from simple buffers (pH 1.2, 6.5, 7.4) the solubility is also tested in biorelevant media that closely simulate the gastrointestinal fluids (Di et al. 2012a). Biorelevant media were developed since the solubility of a drug in water or simple buffers is not always reflective of the solubility in the gastrointestinal lumen (Galia et al. 1998). Especially for lipophilic drugs, biliary secretions or dietary lipids can enhance drug solubility. To consider these differences in *in vitro* experiments, biorelevant media can reflect the osmolality, pH and buffer capacity of gastrointestinal fluids and can include bile components, dietary lipids, lipid digestion products and enzymes. Depending on the investigated drug, not all components and properties of the medium may be necessary to reflect the *in vivo* solubility and thus, the level of the biorelevant medium can be chosen accordingly (Figure 13.1) (Markopoulos et al. 2015).

Please insert Figure 13.1 here

### 2.1.2 *In vitro* release and dissolution testing

Apart from the solubility of a drug, the dissolution rate can also be limiting for the drug absorption of poorly soluble drugs. Additionally, the release of the drug substance from a drug product can be critical for the drug product performance *in vivo*. For development purposes, *in vitro* tests should adequately represent the gastrointestinal physiology to be able to sufficiently reflect drug dissolution, degradation, supersaturation, precipitation and re-dissolution *in vivo* and to guide formulation development (Kostewicz et al. 2014b; Wang et al. 2009). Therefore, the experimental design should consider the composition, volume, flow rates and mixing patterns of the gastrointestinal fluids (Dressman et al. 1998; Fotaki and Vertzoni 2010).

Four dissolution apparatus are included in the United States Pharmacopoeia for oral drug products. In the USP apparatus 1 (Basket Apparatus) the investigated drug product is placed in a spinning basket in the middle of a cylindrical vessel with hemispherical bottom filled with dissolution medium. (US Pharmacopeial Convention 2005) The USP apparatus 2 (Paddle Apparatus) uses the same vessel but a paddle is used as stirring element (US Pharmacopeial Convention 2005). For both apparatus, methods usually use high volumes of dissolution medium (500-1000 mL) to generate sink conditions. Especially in the fasted state, the high volumes are unlikely to match the *in vivo* situation. This is particularly an issue if sink conditions are not maintained *in vivo* resulting in an overestimation of drug dissolution. For drugs with high solubility (BCS class 1 and 3), sink conditions are usually maintained *in vivo*. For drugs with low solubility, the conditions in those dissolution experiments are likely to mismatch the *in vivo* situation. At highest risk are BCS class 4 drugs, since the high membrane permeability of BCS class 2 drugs results in constant removal of dissolved drug from the luminal fluids (Kostewicz et al. 2014b). Furthermore, coning effects and variability in hydrodynamics depending on the investigated dosage form (size, shape, density) and its location in the vessel often result in a lack of correlation to physiological conditions (Kostewicz et al. 2014b). In the USP apparatus 3 (Reciprocating Cylinder) the drug product is placed in a glass tube with a mesh base that reciprocates vertically in a cylindrical, flat-bottomed glass vessel filled with dissolution medium (US Pharmacopeial Convention 2005). Media changes can be easily performed by moving the glass tube from one vessel to another vessel but limit the usage of the apparatus to non-disintegrating dosage forms. Typical volumes of dissolution medium are 250 mL in each glass vessel. Hydrodynamics can be adjusted by changing the rate of the reciprocating movement and mesh size of the sieve. For these three USP apparatus,



the temperature can be controlled with a tempered water-bath surrounding the dissolution vessels. In the USP apparatus 4 (Flow-Through Cell), the drug product is placed in a flow-through cell, through which the dissolution medium can be pumped with an adjustable flow rate (usually 4 to 16 mL/min) and which is immersed in a tempered water bath. The advantages of the flow-through cell are the possibility to change flow rate and media within a single experiment and to maintain sink conditions if the system is used in open mode (continuously fresh dissolution medium from the reservoir) (Fotaki 2011).

Apart from the apparatus described in the USP, various biopharmaceutic tools have been developed to simulate the dissolution process *in vitro*. Biphasic dissolution tests can be useful for poorly soluble compounds as membrane permeation is simulated with an organic layer constantly removing drug from the aqueous medium to maintain sink conditions. Integrated permeation systems such as the  $\mu$ Flux™ (Pion Inc., Woburn, MA, US) have the advantage of simultaneous measurements of dissolution and permeability. Surface dissolution imaging is used to understand surface effects during dissolution and quantify swelling, erosion and disintegration kinetics. The use of physiologically relevant bicarbonate buffers in dissolution tests was shown to be more discriminative for e.g. enteric coated formulations but is laborious and results were shown to be less reproducible (Liu et al. 2011; Boni et al. 2007). Transfer models were able to successfully predict drug precipitation of weak bases *in vivo* by constantly transferring medium from a gastric donor compartment to an intestinal acceptor compartment (Kostewicz et al. 2004). Complex gastrointestinal simulators such as the TNO Gastro-Intestinal Model (TNO, Zeist, Netherlands) simulate the conditions in the lumen of the gastrointestinal tract very closely by mimicking digestive fluids, constant removal of metabolites and control of pH, temperature and luminal transit.

### **2.1.3 Permeability**

For the prediction of the permeability of a compound across the intestinal barrier, several methods can be used ranging from simple filter-immobilized artificial membranes, *in vitro* cell cultures to *in situ* perfusion studies (Table 13.1).

Please insert Table 13.1 here

In the early stages of drug discovery, methods suitable for high throughput screening are used such as parallel artificial membrane permeability assays (PAMPA). PAMPA consists of a microporous filter which is infused by a lipid or a lipid mixture

dissolved in a nonpolar solvent and which separates two aqueous, pH-buffered solutions in a microplate sandwich (Caldwell and Yan 2014). The concentration gradient between the two compartments is the driving force for the permeability of the investigated compound. This driving force can be maintained, and the experimental time can be reduced with the use of a pH-gradient, the addition of cosolvents/solubilizing agents or addition of compounds to simulate protein binding in the donor compartment (Caldwell and Yan 2014).

Other permeability assays use immortalized cell cultures with the ability to form polarised monolayers (with distinct apical and basolateral morphologies) as membranes (Alqahtani et al. 2013). The most commonly used cells are Caco-2 cells, derived from a human colon adenocarcinoma and also available for high throughput screening. Caco-2 cells are usually cultured for at least twenty days to express high amounts of transporter enzymes, form tight junctions and obtain cell polarity (Alqahtani et al. 2013; Bohets et al. 2001). The expression of endogenous transporter systems such as P-glycoprotein (P-gp) and several drug metabolizing enzymes like aminopeptidase, esterase, sulfatase and some CYP450 isoenzymes is the main advantage of Caco-2 cells while paracellular permeability is often under-predicted due to “tighter” tight junctions (Alqahtani et al. 2013; Lea 2015). The use of Madin-Darby canine kidney cells (MDCK), derived from the distal tubular part of the dog kidney, has the advantage of reducing the time needed for the formation of a polarised monolayer with well-defined tight junctions. Additionally, the transepithelial electrical resistance (TEER) is lower compared to Caco-2 cells indicating increased “leakiness” (Braun et al. 2000). The non-human origin of these cells has the disadvantage of different enzyme and transporter expression. To overcome this issue, it is possible to transfect the cells with e.g., P-gp, MRPs (Multidrug Resistance-associated Protein) or BCRP (Breast Cancer Resistance Protein). To only investigate passive permeability, special cell lines with low expression of endogenous canine transporters such as MDCKII-Low Efflux cells can be used (Di et al. 2011). The apparent permeability observed using cultured cell lines must be normalized according to accessible intestinal surface area, paracellular permeability, pH dependence, resistance of the aqueous boundary layer and transcellular permeability to predict the effective permeability *in vivo* (Avdeef 2012).

Additionally, permeability can be assessed *ex vivo* using Ussing chambers. An excised intestinal segment (from rat, mouse, rabbit, dog, monkey or human) is mounted between two diffusion cells usually filled with Krebs-Ringer bicarbonate buffer (Alqahtani et al. 2013). Despite the supply of nutrients and carbogen gas during the experiment, tissue viability can only be maintained for 2-3 hours. The

method results in good predictions of intestinal drug absorption and provides information about influx/efflux transport and drug metabolism.

A labour-intensive method is the *in situ* perfusion model. This includes the perfusion of an isolated intestinal segment of the small bowel of rats with a solution containing the investigated drug (Alqahtani et al. 2013). The rat is unconscious during the experiment and its body temperature is controlled with a heating pad or an overhead lamp (Stappaerts et al. 2015). Drug permeability can then be calculated by the difference between inlet and outlet flow of the investigated drug. To account for differences in drug concentration due to water absorption or secretion, non-absorbable markers (e.g., phenol red) or gravimetric methods can be used (Stappaerts et al. 2015). The method allows distinction between regional permeability differences and considers active transport mechanisms. Additionally, intestinal metabolism can also be investigated for example by concomitant administration of inhibitors of metabolizing enzymes or by mesenteric blood sampling (Stappaerts et al. 2015). By considering only the difference in drug perfusate concentration, drug absorption may be overestimated for drugs that are accumulated in the gut wall or metabolised by intestinal enzymes. Furthermore, the use of anaesthesia can have a possible impact on drug permeability.

#### **2.1.4 Active transport**

The involvement of active transport mechanisms in the membrane permeation of a drug can mediate or limit its absorption but also be responsible for Drug-Drug interactions. Bioavailability can be increased by drug transport from the luminal to the basolateral site via influx transporters or decreased by transport in opposite direction via efflux transporters.

The *in vitro* assessment of active transport mechanisms includes cell-based and subcellular assays. In both cases, cells are incubated with a drug solution followed by the monitoring of changes in drug concentration. In cell-based assays, transport proteins are over-expressed in a transfected cell line such as MDCK cells, HEK (Human Embryonic Kidney) or LLC-PK<sub>1</sub> (Lewis Lung Carcinoma-Pig Kidney) (Caldwell and Yan 2014). Another approach is to partially or completely silence (knock down) a natively expressed transporter protein in a cell line, for example, P-gp in Caco-2 cells and compare the drug permeability to the unmodified cell line (Caldwell and Yan 2014). Other methods for active transport studies include the use of primary

cells such as hepatocytes and membrane vesicles (described in detail below in Section 12.5.1).

### **2.1.5 Gut wall metabolism**

The intestine with numerous metabolizing enzymes is involved in the metabolism of compounds undergoing Phase 1 and 2 reactions. Several *in vitro* methods are available to investigate intestinal drug metabolism. For drugs that are rapidly metabolised, suitable methods include the use of isolated intestinal perfusion, the everted sac method and Ussing chambers (van de Kerkhof et al. 2007). For isolated intestinal perfusions, a segment of the intestine is removed from an animal (e.g. rat) and placed in a bath filled with buffer followed by perfusion with the investigated compound from the luminal or vascular side (van de Kerkhof et al. 2007). The everted sac method includes eversion of intestine (most often from rat) and its cannulation from both sides followed by drug perfusion. Disadvantages of these two methods are their limitation to short-term incubation and the animal origin of the tissue. The Ussing chamber, as described above in Section 2.1.3, can also be used for investigations of intestinal drug metabolism.

For drugs that are slowly metabolised, more appropriate *in vitro* tools for gut wall metabolism are biopsies, intestinal precision-cut slices (thickness 250-400  $\mu\text{m}$ ) and primary cells.(van de Kerkhof et al. 2007) Limitations of these methods are that it is not possible to study the direction of excretion and the very difficult isolation procedures for primary enterocytes.(van de Kerkhof et al. 2007)

For mechanistic investigations of relevant metabolic enzymes, interaction studies and enzyme kinetics, *in vitro* assays include subcellular fractions from enterocytes and cell cultures similarly to the assays for hepatic metabolism as further discussed below in Section 4.1.

## 2.2 *In silico* methods

### 2.2.1 Solubility

In the initial stages of drug development, *in silico* solubility predictions are used to screen new chemical entities for drug-like characteristics. A large number of *in silico* tools is available for the prediction of aqueous solubility based on training sets of experimental data and either experimentally determined properties or computational 1D, 2D and 3D molecular descriptors such as hydrophobicity, molecular surface area and electron distribution (Figure 13.2)(Dokoumetzidis et al. 2007). The lipophilicity ( $\log P$ ,  $\text{clog} P$ ), the size of the molecule and the surface area of the non-polar atoms have been identified as the most important predictors for aqueous solubility.(Dokoumetzidis et al. 2007)

Please insert Figure 13.2 here

Aqueous solubility is determined by the sublimation energy and hydration energy of a drug. The extensively-used modified Yalkowsky's general solubility equation (Eq. 13.1) describes the water solubility of a molecule ( $S_0(M)$ ) using the logarithm of the octanol/water partition coefficient ( $\log P_{Oct}$ ) to reflect the hydration energy and the melting point ( $m.p.$ ) to reflect the crystal lattice energy (Jain and Yalkowsky 2001).

$$\log S_0(M) = -\log P_{Oct} - 0.01(m.p. - 25) + 0.50 \quad (13.1)$$

For highly lipophilic drugs, micellar solubilisation can improve drug solubility, while for drugs with a high melting point solubility can be improved by modifications of the structure resulting in a reduction of lattice energy.(Sugano 2012) To consider ionisation effects it has been proposed to use the logarithm of the distribution coefficient ( $\log D$ ) at pH 7.4 instead of the  $\log P_{Oct}$  for the solubility prediction.(Hill and Young 2010)

For weakly acidic and basic drugs, differences in drug solubility along the gastrointestinal tract can be a result of drug ionisation. pH-dependent solubility profiles can be predicted *in silico* using the Henderson-Hasselbalch equation.(Hansen et al. 2006) Additionally, the aqueous solubility may differ from the solubility in gastrointestinal fluids, especially for lipophilic compounds, due to e.g. luminal surfactants such as bile salts or lecithin. If reliable predictions of drug solubility in gastrointestinal fluids could be obtained using computational models, this could replace

laborious biorelevant solubility studies. For several compounds, successful predictions for the increase in solubility as a function of bile salt concentrations could be made using an empirical equation introduced by Mithani *et al.*, 1996 (Eq. 13.2 and 13.3) (Mithani *et al.* 1996).

$$\log SR = 2.09 + 0.64 \log P \quad (13.2)$$

$$C_{SX} = C_{SO} + (SC_{bs})(MW)([NaTC]) \quad (13.3)$$

where  $SR$  is the solubilisation ratio,  $C_{SX}$  is the solubility [ $\mu\text{g/mL}$ ] in the presence of taurocholate,  $C_{SO}$  is the aqueous solubility [ $\mu\text{g/mL}$ ],  $MW$  is the molecular weight and  $[NaTC]$  is the concentration of sodium taurocholate. It should be noted that the equation only considers the effect of sodium taurocholate, but gastrointestinal fluids are more complex containing e.g. lipids and mixed micelles as colloidal aggregates.

For solvation processes, Abraham *et al.* (1987) described a solvation-related property based on several parameters such as the McGowan's characteristic volume, hydrogen-bonding acidity and basicity, polarizability and an excess molar refraction descriptor. These Abraham solvation predictors have been successfully used to predict the solubility enhancement in biorelevant media (Fasted State Simulated Intestinal Fluid) compared to a simple buffer (Niederquell and Kuentz 2018). Most prominent were a positive effect of McGowan's characteristic volume and a negative effect of drug basicity on solubility enhancement.

## 2.2.2 Drug release and dissolution

In most oral dosage forms, the active pharmaceutical ingredient is administered in solid form. For these formulations, the drug needs to be released from the formulation and dissolve in the gastrointestinal fluids prior to its intestinal membrane permeation. If drug dissolution occurs slowly in the gastrointestinal tract, it can be the limiting step for drug absorption. Diffusion theory is widely used to describe particle dissolution assuming drug dissolution is controlled by the diffusion of the solute through a stagnant diffusion layer surrounding solid particles.

In 1897, it was shown by Noyes and Whitney (1897) that the rate of drug dissolution is proportional to the difference between the saturation solubility ( $C_s$ ) and the present drug concentration at time  $t$ . This relationship was further modified to the Nernst-Brunner law

$$\frac{dC}{dt} = \frac{DS}{Vh}(C_s - C_t) \quad (13.4)$$

where  $C$  is the concentration,  $t$  is the time,  $D$  is the diffusion coefficient,  $S$  is the surface of the solid particles,  $V$  is the volume of the dissolution medium and  $h$  is the thickness of the diffusion layer. (Brunner 1904; Nernst 1904) This dissolution model is still widely used today. (Dokoumetzidis et al. 2007) The diffusion coefficient can be derived from the Stokes-Einstein equation or the Hayduk-Laudie equation for non-electrolytes. (Hayduk and Laudie 1974) A further improvement was made by Wang and Flanagan resulting in a generalised diffusion layer model for spherical particles (Eq. 13.5 that considers a time-dependent reduction of the particle radius, a nonlinear concentration gradient in the diffusion layer and changes in the thickness of the effective boundary layer (Wang and Flanagan 1999, 2002).

$$\frac{dC}{dt} = -4\pi r_t^2 * D * \left[\frac{1}{r_t} + \frac{1}{h}\right] * [C_s - C_t] \quad (13.5)$$

The particle radius,  $r_t$ , is time dependent and influences the thickness of the effective boundary layer  $h$ . In the case of small particles ( $r < 30 \mu\text{m}$ ) the particle radius is considered to be equal to  $h$ , while for larger particle radii ( $r > 30 \mu\text{m}$ )  $h$  is set to  $30 \mu\text{m}$  (Peters 2012).

For particles with substantially larger diameters compared to the diffusion layer thickness, the diffusion layer can be assumed as planar resulting in the cube root equation:

$$Q^{\frac{1}{3}} = Q_0^{\frac{1}{3}} - k_{1/3}t \quad (13.6)$$

with the cube roots of the weight of a spherical particle at time 0,  $Q_0^{\frac{1}{3}}$ , and time  $t$ ,  $Q^{\frac{1}{3}}$ , and the cube root rate constant,  $k_{1/3}$ , as described by Hixson and Crowell (Hixson and Crowell 1931). The cube rate constant can be further described as:

$$k_{1/3} = \left(\frac{\pi}{6\rho^2}\right)^{1/3} \frac{2DC_s}{h} \quad (13.7)$$

with  $D$  as the diffusion coefficient,  $C_s$  as the equilibrium solubility,  $h$  as the thickness of the diffusion layer and  $\rho$  as the density.

For the modeling of *in vitro* dissolution data, fitting of the data can be obtained using empirical equations. The Weibull equation (Equation 8) is the most commonly used equation due to its flexibility to fit almost any dissolution data

$$W_t = W_{max} \left[ 1 - e^{-\left(\frac{(t-T_{lag})^b}{a}\right)} \right] \quad (13.8)$$

where  $W_t$  is the amount dissolved at time  $t$ ,  $W_{max}$  is the maximum amount dissolved,  $t$  is time,  $T_{lag}$  is the lag time before the onset of dissolution,  $a$  is a scale parameter and  $b$  is a shape parameter characterizing the curve (exponential curve  $b=1$ , sigmoid curve  $b > 1$ , parabolic curve  $b < 1$ ). (Langenbucher 1972) Other empirical approaches include gamma distribution, power laws, discrete time-step difference equations and stochastic differential equations. (Dokoumetzidis et al. 2007) For *in vivo* predictions of drug dissolution, parameters with physical meaning derived from mechanistic models are usually used in absorption models. (Dokoumetzidis et al. 2007)

In certain cases, drug absorption can also be determined by the release of a drug from the formulation. Controlled-release formulations are for example developed to reduce dosing frequency, to avoid toxicity for drugs with a narrow therapeutic index or to locally deliver drugs in the gastrointestinal tract. The drug release rate of these formulations is constant over a certain time and is diffusion-controlled, swelling-controlled or chemically-controlled (Siepmann and Peppas 2011). This steady release process allows the direct use *in vitro* release profiles for *in vivo* predictions or even to use empirical equations. For the analysis of drug release data, the Higuchi model (Equation 9) is widely used but should only be applied to the first 60% of drug release

$$\frac{q(t)}{q_{\infty}} = k\sqrt{t} \quad (13.9)$$

with  $q(t)$  as the drug released at time  $t$ ,  $q_{\infty}$  as cumulative amount of drug released at infinite time and the constant  $k$ . (Higuchi 1961) Assumptions behind this model are that the carrier is of a thin planar geometry and the medium acts as a perfect sink. Adapted models for carriers with different geometries have been proposed in literature (Baker 1987). Other models used for drug release are the Peppas equation, Weibull equation, Baker and Lonsdale equation, Hixson and Crowell equation or Monte Carlo simulation methods (Carbinatto et al. 2014).

### 2.2.3 Permeability

*In silico* approaches to predict passive permeability of novel compounds are mostly developed based on data sets of compounds with known *in vitro* permeability in different cell lines (e.g. Caco-2, MDCK, PAMPA) and are used in drug discovery for



the selection of novel compounds for synthesis (Broccatelli et al. 2016). Often these *in silico* models are based on multivariate statistical analysis (e.g. partial least-squares regression) that correlate *in vitro* results to 2D or 3D molecular descriptors (Zhang et al. 2006; Broccatelli et al. 2016). Other *in silico* approaches include mechanistic mathematical models developed for the passive transcellular drug transport which are for example based on simple physicochemical properties such as logP and pKa (Zhang et al. 2006). Such mechanistic models describing passive permeability can be augmented with additional processes such as active influx and efflux transport. This more complex system description can be used to define the properties of the enterocyte as a separate compartment for absorption (Dokoumetzidis et al. 2007). Such models are for example implemented in PBPK models that are commercially available such as the software SimCyp® (Certara, Sheffiled, UK) or GastroPlus™ (Simulations Plus, US).

#### **2.2.4 Active transport**

Drug-transporter interactions can be modeled *in silico* either based on a set of compounds with known transporter activity (substrate-based methods) or based on the 3D-structure of the transporter (transporter-based methods) (Chang and Swaan 2006). Substrate-based methods use molecular descriptors or chemical properties for pharmacophore or 3D-QSAR modeling without the need for prior information about the structure of the transporter. Such models exist for a variety of different transporters such as P-glycoprotein, organic cation and anion transporters, bile acid transporters and nucleoside transporters (Chang and Swaan 2006). Transporter-based methods include ab initio modeling and homology modeling. Ab initio modelling generates the 3D structure of the transport protein from its primary sequence, while homology modeling uses structural information of a template protein with mutual sequence similarity (Chang and Swaan 2006).

For the modeling of active carrier-mediated transport most often the saturable Michaelis–Menten kinetic is used. The input parameters  $V_{\max}$ , the maximum reaction velocity, and  $k_m$ , the substrate concentration with 50%  $V_{\max}$  (Michaelis constant) are determined *in vitro*. While at low concentrations the rate of transport increases almost linear, at high concentrations enzyme saturation occurs resulting in a constant maximum transport rate.

### 2.2.5 Gut wall metabolism

For *in silico* predictions of gut wall metabolism, an allometric scale-up approach is followed if *in vitro* data is available. For example, the slice weight and organ weight are used for the scaling of experimental data from precision-cut intestinal slices to the *in vivo* situation. Alternative approaches include scaling of the information of specific enzymes determined for hepatic metabolism to the gut wall metabolism. Therefore, information about the kinetics of the specific enzymatic reaction, enzyme abundance in the *in vitro* assay used for the determination of the kinetics of the enzymatic reaction and enzyme scaling factors (e.g. derived from immunoquantified enzyme expression levels in intestine and liver) are needed (Heikkinen et al. 2012). With these approaches, the intrinsic intestinal clearance is determined and can further be used to calculate the fraction of drug escaping gut wall metabolism. Using a similar approach to the well-stirred liver model, the fraction of drug escaping gut wall metabolism ( $F_g$ ) can be described with the  $Q_{gut}$ -model:

$$F_g = \frac{Q_{gut}}{Q_{gut} + f_{u,g} * CL_{u,int,g}} \quad (13.10)$$

where  $f_{u,g}$  is the fraction of unbound drug in the enterocytes and  $CL_{u,int,g}$  is the intrinsic metabolic clearance in the gut (Yang et al. 2007).  $Q_{gut}$  can further be described as:

$$Q_{gut} = \frac{Q_{villi} * CL_{perm}}{Q_{villi} + CL_{perm}} \quad (13.11)$$

where  $Q_{villi}$  is the villous blood flow and  $CL_{perm}$  is the cellular permeability. Purely *in silico* approaches are used to identify the investigated compound as a substrate for specific enzymatic reactions following ligand-based or structure-based approaches as further described below in Section 12.4.2.

### 2.2.6 Dynamic transit models

Dynamic transit models are dependent on a temporal variable and include mixing tank models, the Compartmental Absorption Transit model (CAT) and dispersion models. (Yu et al. 1996) With these models it is not only possible to predict the fraction of dose absorbed but also to predict the rate of drug absorption which can

help in the simulations of plasma concentration profiles and predictions of *in vivo* performance.

The mixing tank model introduced by Dressman and Fleisher (1986) is based on mass balance considerations and suitable for drugs with dissolution-rate limited absorption. The model considers the gastrointestinal tract as a single well-stirred compartment with uniform drug concentration, in which transit and absorption follow first-order kinetics. The drug is administered as bolus and the transport of solid and dissolved drug occurs at the same rate. Despite several limitations of the model such as no consideration of luminal degradation, gut metabolism or heterogeneity of the gastrointestinal tract, the model could successfully predict the determining factors limiting the absorption of digoxin (dissolution rate) and griseofulvin (solubility).

The Compartmental Absorption Transit model (CAT) model considers the gastrointestinal tract as a series of well-stirred compartments with different volumes and flow rates but equal residence time of the drug. For the small intestine, seven compartments resulted in the best fit of available literature data. (Yu and Amidon 1999) Further modifications of the CAT model included addition of compartments of un-released drug and undissolved drug, pH-dependent solubility, precipitation, gastric and colonic compartments, information of effective absorptive surface area and drug transporter processes resulting in the Advanced Compartmental Absorption Transit (ACAT™), the basis of the commercial software GastroPlus™ (Simulations Plus, US). (Kuentz 2008)

The current version of the ACAT™ model considers ionisation effects on solubility and permeability, paracellular permeability, nanoparticles effects, food effects, bile salt-enhanced solubility, precipitation and active transport. It can be used for immediate release, delayed release and controlled release formulations. Apart from human gut physiology, physiological gut models are available for a variety of species (dog, rat, mouse, rhesus monkey, cynomolgus monkey, minipig, rabbit and cat). Drug dissolution can be predicted with several dissolution models (e.g., Hintz and Johnson equation, Wang and Flanagan equation, Z-Factor Model). (Hintz and Johnson 1989; Takano et al. 2006) A similar advanced compartmental absorption models is integrated in the SimCYP® software (Certara, Sheffield, UK) under the name Advanced Dissolution Absorption Metabolism (ADAM) model. The ADAM model uses the Wang and Flanagan equation (described above in Section 2.2.2) as default model for drug dissolution (Wang and Flanagan 1999).

The dispersion models consider the gastrointestinal tract as a continuous single tube with constant velocity, dispersion behaviour and concentration profile across

the tube diameter and spatially varying properties along the tube (Yu et al. 1996). The convection-dispersion equation is used to describe the drug absorption process:

$$\frac{\partial C}{\partial t} = \alpha \frac{\partial^2 C}{\partial x^2} - \beta \frac{\partial C}{\partial x} - \gamma C \quad (13.12)$$

where  $C$  is the concentration,  $x$  is the axial distance from the stomach,  $\alpha$  is the dispersion coefficient,  $\beta$  is the linear flow velocity in the axial direction and  $\gamma$  is the drug absorption rate constant (Ni et al. 1980). With a modified version of this concept, drug absorption in rats and later in humans was successfully predicted (Willmann et al. 2003; Willmann et al. 2004). The earlier versions of the absorption model of the PBPK software PK-Sim® (Open Systems Pharmacology) were evolved from this model which was later replaced by a twelve compartmental absorption model (Willmann et al. 2012).

### 3. Distribution

#### 3.1 *In vitro* methods

Plasma Protein Binding (PPB) is an important parameter for the distribution of a drug in the body. Highly protein bound drugs are retained in plasma and often less prone to distribute into body tissues resulting usually in a low volume of distribution. In terms of pharmacodynamics, highly protein-bound drugs may not reach therapeutic concentrations as usually only the fraction unbound is available for receptor or enzyme interaction. Plasma contains 7% proteins of which human serum albumin is the most important protein for drug binding followed by  $\alpha_1$ -acid glycoprotein and lipoproteins (Caldwell and Yan 2014). The preferred method for the determination of plasma protein binding is equilibrium dialysis since the method is less susceptible to non-specific binding. For classical equilibrium dialysis (CED), a regenerated cellulose membrane (cut-off 12-14 kDa) separates two 1 mL paired Teflon cells filled with buffer and plasma which are tempered at 37°C and rotated for a predetermined period (4-12 h) (Caldwell and Yan 2014). Typical methods used for drug analysis are scintigraphy or LC-MS/MS analysis. Further development of the method resulted in the Rapid Equilibrium Dialysis (RED) with faster preparation and equilibration times and suitability for higher throughput of samples. Another method to determine PPB is ultracentrifugation where plasma is added to the device followed by centrifugation for 10–20 min at 1000–2000 × g in a fixed angle rotor (Caldwell and Yan 2014). The accuracy of this method is limited

by the non-specific binding to the filtration apparatus. Additionally, high performance affinity chromatography can be used to determine PPB using immobilized albumin or  $\alpha_1$ -acid glycoprotein as stationary phase and correlate chromatographic retention to the percentage of drug binding to albumin or  $\alpha_1$ -acid glycoprotein (Lambrinidis et al. 2015). Longer chromatographic retention time indicates higher percentage of protein binding.

Similar to PPB, drug partition into red blood cells (RBC), the major cellular component of blood, can influence drug distribution. For the *in vitro* determination of RBC partitioning, radiolabelled or unlabelled drug is mixed with whole blood followed by centrifugal separation of RBC and plasma and the determination of drug concentration in both compartments (Hinderling 1984). Measurements at several time points also permit to determine the rate of RBC partitioning.

*In vitro* tissue distribution can be assessed using tissue homogenates, tissue slices or isolated tissue components. After an incubation period of the tissue with the investigated drug, the tissue-to-medium distribution coefficient can be calculated using the separately measured drug concentration in tissue and medium (Ballard et al. 2003). While tissue homogenates are the most widely used method, the disruption of cellular integrity can result in an overestimation of tissue distribution for drugs mainly restricted to the extracellular space.

### 3.2 *In silico* methods

Computational models to predict plasma protein binding have been developed using ligand-based approaches with quantitative structure activity relationships and structure-based approaches focusing on the crystal structure of drug-protein complexes. Due to the predominant role of human serum albumin in PPB, most approaches only focus on albumin and only recently advances for  $\alpha_1$ -acid glycoprotein have been made. Due to the different binding sites of albumin, global models for a broad range of compounds are challenging and in the beginning *in silico* models focused on similar compounds using the same binding site. Based on training sets of compounds and multivariate statistical analysis, lipophilicity (logP), electronic properties, acidity, shape modulating factors, polarity terms and fraction ionised (cationic and anionic) were identified as important predictive factors in ligand-based *in silico* models (Lambrinidis et al. 2015).

Drug distribution in the body has been described by different mechanistic models. The steady state volume of distribution ( $V_{ss}$ ) describes the extent of tissue distribution and can be defined as:

$$V_{ss} = (\sum V_t * P_{t:p}) + (V_e * E:P) + V_p \quad (13.13)$$

where  $V_t$  is the fractional volume of a tissue,  $P_{t:p}$  is the plasma:partition coefficient,  $V_e$  is the fractional volume of erythrocytes,  $E:P$  is the erythrocyte:plasma ratio and  $V_p$  is the plasma volume. (Poulin and Theil 2002) The erythrocyte:plasma ratio can be described as:

$$E:P = [B:P - (1 - Ht)]/Ht \quad (13.14)$$

where  $B:P$  is the blood:plasma ratio which can be determined *in vitro* (as described above in Section 12.3.1) and  $Ht$  is the haematocrit (volume percentage of red blood cells in blood) (Poulin and Theil 2002).

Literature data is available for the different body volumes (e.g., lung, brain, heart, liver, bone, kidney, muscle, skin, adipose) in Equation 13 and for the estimation of tissue:plasma partition coefficients the following *in silico* models can be used.

An *in silico* model developed by Poulin and Theil (2002) and modified by Berezhkovskiy (2004) accounts for plasma and tissue being composed of neutral lipids, phospholipids and water and only the unionised fraction of the drug permeating the membrane. This resulted in the following description of the tissue-partition coefficient,  $P_{t:p}$ , for non-adipose tissue:

$$P_{t:p} = \frac{[P_{o:w}(V_{t,nl} + 0.3V_{t,ph}) + 0.7V_{t,ph} + \frac{V_{t,w}}{fu_t}]}{[P_{o:w}(V_{p,nl} + 0.3V_{p,ph}) + 0.7V_{p,ph} + \frac{V_{p,w}}{fu_p}]} \quad (13.15)$$

where  $P_{o:w}$  is the n-octanol:buffer partition coefficient of the non-ionized species,  $V$  is the fractional tissue volume content of neutral lipids ( $nl$ ), phospholipids ( $ph$ ), and water ( $w$ ) in either tissue ( $t$ ) or plasma ( $p$ ) and  $fu$  is the fraction unbound. The fraction unbound in tissue,  $fu_t$ , can mechanistically be estimated (Eq. 13.16) from the fraction unbound in plasma according to

$$fu_t = \frac{1}{\left[\frac{1-fu_p}{fu_p}\right]^{*0.5}} \quad (13.16)$$

as described by Poulin and Theil (2000).

Further models developed by Rodgers and Rowland differentiated between intra and extracellular space and added an acidic phospholipid fraction in tissues resulting in an improvement of the prediction for strong bases. (Rodgers et al. 2005a, b; Rodgers and Rowland 2006, 2007) Additionally to passive permeability of the un-

ionised fraction of the drug, a further modification of the model includes membrane permeability of the ionized fraction and is integrated in the SimCyp® simulator (Certara, Sheffield, UK).

## 4. Metabolism

Drug metabolism or biotransformation of orally administered drugs occurs mainly in the small intestine (as described above in Section 2.1.5) and liver. Physicochemical characteristics of drugs such as a high lipophilicity as indicated by a high  $\log D_{7.4}$  were shown to be associated with high metabolic clearance (van de Waterbeemd and Gifford 2003). A variety of metabolizing enzymes is available to facilitate the excretion of xenobiotics by increasing their aqueous solubility. Enzymatic biotransformation can be divided in Phase 1 and Phase 2 metabolism. Phase 1 reactions are reactions of functionalisation (e.g. oxidation, hydrolysis or reduction) that introduce polar functional groups to molecules resulting in either facilitated excretion or further metabolism (Westhouse and Car 2007). In Phase 2 reactions, large polar molecules (e.g. glucuronate, acetate and sulfate) are conjugated to drug molecules further resulting in an increased aqueous solubility to facilitate excretion (Westhouse and Car 2007).

### 4.1 *In vitro* methods

Different *in vitro* assays are available to predict hepatic drug metabolism. Recombinant CYP enzymes expressed in different cell types can be used to identify the specific CYP enzymes involved in the metabolism of the investigated drug. Additionally, incubation of these recombinant CYP enzymes with the investigated compound provides information about the metabolic enzyme activity per mass of protein which can further be scaled up to the *in vivo* situation.

The homogenization of liver and subsequent centrifugation at 1000 g and 9000 g, separates the pellet with nuclei and mitochondria, respectively from the supernatant with cytosolic and microsomal enzymes (Richardson et al. 2016). The supernatant is the hepatic S9 pool and can be used as *in vitro* system for investigating hepatic metabolism. An additional ultracentrifugation step at 100000 g results in the separation of the cytosol subcellular fraction in the supernatant and the microsomal subcellular fractions in the pellet (Richardson et al. 2016). The human liver microsomes are commonly used in the pharmaceutical industry due to their richness of metabolic Cytochrome P450 enzymes, low cost and ease in use (Di et

al. 2012b). However, metabolic pathways in the assay can be incomplete since the present enzymes are limited to enzymes contained in endoplasmic reticulum (Phase 1 reactions) (Richardson et al. 2016).

Primary hepatocytes, taken from living tissue (e.g. biopsy material), are grown *in vitro* and represent more closely the *in vivo* situation due to the full range of metabolic enzymes (e.g., aldehyde oxidase and monoamine oxidase), cofactors and membrane transporters (Di et al. 2012b). Since it is not possible to culture primary hepatocytes indefinitely, cryopreservation of hepatocytes was introduced. This resulted in constant availability of the *in vitro* assay in the drug discovery setting by retaining the full activity during storage of the hepatocytes in liquid nitrogen for one year. When comparing assays of liver microsomes with hepatocytes, intrinsic clearance of compounds metabolised over non-CYP pathways was faster in hepatocytes (Di et al. 2012b). On the other hand, the intrinsic clearance of drugs with rate-limiting hepatic uptake was faster in microsomes (Di et al. 2012b).

#### 4.2 *In silico methods*

For the prediction of hepatic metabolic clearance *in vivo*, the previously mentioned *in vitro* assays (S9 pool, liver microsomes, hepatocytes) can be scaled to the *in vivo* situation. For example, the intrinsic clearance of the unbound fraction of the drug in a human liver microsome assay is given in  $\mu\text{l}/\text{min}/\text{mg}$  protein and can be scaled up to the *in vivo* situation based on information about the level of microsomal proteins per gram of liver and liver weight. The hepatic clearance is also dependent on the amount of drug that comes into contact with the hepatic metabolizing enzymes that can further depend on e.g. hepatic blood flow or fraction unbound in blood. For the hepatic clearance,  $CL_h$ , most often the well-stirred liver model is used:

$$CL_h = \frac{Q_h * f_{ub} * CL_{int}}{Q_h + f_{ub} * CL_{int}} \quad (13.17)$$

where  $Q_h$  is the hepatic blood flow,  $f_{ub}$  is the fraction unbound in blood and  $CL_{int}$  is the intrinsic hepatic clearance (Pang and Rowland 1977). Assumptions behind this model are an instant equilibrium between hepatocytes and adjacent blood and a homogenous drug distribution in the liver. In contrast, the parallel tube model considers that the drug concentration decreases along the direction of the blood flow (Pang and Rowland 1977).

For the prediction of drug metabolism only with *in silico* methods, ligand-based approaches or structure-based approaches have been used especially for CYP enzymes. Ligand-based approaches, such as QSAR, pharmacophore-based algorithms



or shape-focused models, consider the chemical structure and properties of the drugs while structure-based approaches also model the interaction between the investigated substrate and the metabolic enzyme (Andrade et al. 2014; de Groot 2006).

## 5. Excretion

The removal of unaltered drug and its metabolites from the body is known as excretion. Apart from the rate of metabolism, drug clearance from blood is influenced by the biliary and urinary excretion rate of unchanged drug. Drug elimination occurs mainly via the highly perfused primary eliminating organs liver and kidney and is dependent on the physicochemical and structural characteristics of the drugs. Lipophilic drugs with a high molecular weight are often associated with biliary excretion (Ghibellini et al. 2006).

Drug excretion into urine via the kidney, known as renal clearance, is a complex process involving passive glomerular filtration, active tubular secretion, passive and active re-absorption (Paine et al. 2010). If the drug is only cleared by filtration, the renal clearance equals the mathematical product of fraction unbound and glomerular filtration rate ( $f_u \times \text{GFR}$ ). If the renal clearance exceeds this mathematical product, the drug may be a substrate for active tubular secretion by transporters. If the renal clearance is inferior to this mathematical product, it can be assumed that the drug gets reabsorbed. The importance of renal elimination is highlighted by the fact that 32% of the top 200 prescribed drugs in the United States in 2010 were at least partially excreted unchanged in urine ( $\geq 25\%$ ) (Morrissey et al. 2013).

### 5.1 *In vitro* methods

Several *in vitro* methods can be used to study biliary excretion: sandwich-cultured hepatocytes, suspended hepatocytes, vectoral transport using polarized cell lines, single-cell expression systems and membrane vesicles (Ghibellini et al. 2006).

Sandwich-cultured hepatocytes, from rat or human origin, have the advantage that basolateral uptake and canalicular efflux transport can be studied and metabolic functions are retained (Ghibellini et al. 2006). In contrast to the conventionally cultured hepatocytes, the culturing of hepatocytes between two layers of gelled collagen enhances cell viability and allows the formation of functional bile

canalicular networks and polarized excretory function (Swift et al. 2010). Suspended hepatocytes are relatively cheap, easy-to-handle and can be used for up to 4 h (Elaut et al. 2006). Their use is limited to the investigation of uptake mechanisms and metabolism since it is not possible to discriminate canalicular excretion from sinusoidal efflux (Swift et al. 2010). Cell lines (e.g. MDCK), transfected with transporter proteins such as multidrug resistance-associated protein 2 (MRP2), organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 and grown on a permeable membrane, are used to determine the contribution of an individual transport protein, identify driving forces and identify inhibitors (Ghibellini et al. 2006). While the extrapolation to the *in vivo* situation is difficult as these cell lines are less representative of hepatocytes (different expression levels of transport proteins, no complete set of transport proteins, metabolic enzymes and co-factors), the transfected systems are routinely used in drug development due to their ease-in-use and good availability (Ghibellini et al. 2006; Swift et al. 2010). Single-cell expression systems such as *Xenopus laevis* oocytes can transiently express membrane transporters and channels following the injection of their cRNA (Bröer 2010). These expression systems are mainly used to study the mechanism of transport and the effect of genetic diseases (Ghibellini et al. 2006). Inside-out plasma membrane vesicles from cell lines (e.g. insect or mammalian cells) transfected with specific membrane proteins were used to study polymorphisms and substrate specificity of efflux transporters (Ghibellini et al. 2006). For insect cells, the modification of the membrane composition (addition of cholesterol) results in a similar transporter function to mammalian cells (Caldwell and Yan 2014).

In terms of renal excretion different *in vitro* experiments can be used for the processes of passive tubular reabsorption and active tubular secretion and reabsorption. For passive tubular permeability, similar *in vitro* assays as for intestinal permeability are used with cell lines such as LLC-PK<sub>1</sub>, MDCK and Caco-2 (Scotcher et al. 2016a). The proximal tubule cell line, LLC-PK<sub>1</sub>, derived from pig (*Sus scrofa*) kidney, is grown on permeable filter membranes and has been used for transepithelial transport studies investigating the renal disposition of drugs. Apart from the formation of polarized cell monolayers, this cell line has the benefit of expressing endogenous transport proteins (P-gp, MRP2, BCRP) (Kuteykin-Teplyakov et al. 2010; Takada et al. 2005). Recently, the bidirectional epithelial permeation of twenty compounds was studied in this cell line and good correlations to human renal clearance of drugs were obtained after upscaling of the *in vitro* parameters (Kunze et al. 2014). For anionic drugs, however, clearance was underpredicted due to restricted secretion in LLC-PK<sub>1</sub> cells indicative of limited activity of organic anion transporters (Kunze et al. 2014). To closer mimic the conditions in the kidney, the apical to basolateral pH gradient should be considered in the experimental design

and the experimental results should be scaled by the corresponding tubular surface area (Scotcher et al. 2016b).

For active tubular secretion and reabsorption, similar *in vitro* techniques are used as for metabolism or biliary excretion. The range of *in vitro* assays includes membrane vesicles, transfected cells (e.g. Organic Anion Transporter 1-expressing Chinese Hamster Ovary cells (CHO-OAT1), Organic Anion Transporter 3-expressing Human Embryonic Kidney cells 293 (HEK293-OAT3)), immortalised kidney cell lines, primary cultured renal tubule cells and kidney slices (Scotcher et al. 2016a). Human kidney slices can be used to investigate drug uptake at the basolateral membrane but lack information about tubular reabsorption (Watanabe et al. 2011). Their use is restricted due to the limited tissue availability but, if available, complex studies with multiple transporter substrates or inhibitors can be performed with the full set of endogenous transporters (Scotcher et al. 2016a).

## 5.2 *In silico* methods

Considering biliary excretion, several *in silico* models have been developed based on QSAR and compound data of *in vivo* rat biliary excretion. One of these models was developed using principal component regression analysis based on rat biliary excretion data from 56 compounds and 2D molecular descriptors which revealed hydrophobicity (cLogD) as most important factor for the prediction of biliary excretion (Chen et al. 2010). Another model used similar data from 50 compounds and identified a correlation of polar surface area, presence of a carboxylic acid moiety and free energy of aqueous solvation with biliary excretion (Luo et al. 2010). A model, based on 217 compounds, was developed using a simple regression tree model with the Classification and Regression Trees (CART) algorithm and revealed higher biliary excretion for relatively hydrophilic and large compounds, especially when anionic or cationic (Sharifi and Ghafourian 2014).

A variety of *in silico* approaches have been used for the prediction of renal excretion. Allometric models were developed for the prediction of renal clearance in men from animal data (Mahmood 1998; Paine et al. 2011; Lave et al. 2009). Appropriate upscaling of the *in vitro* result to the *in vivo* situation is necessary, as for *in vitro* assays (Kunze et al. 2014). *In silico* models focusing on the likelihood or extent of renal clearance were developed based on QSAR approaches using Volsurf descriptors (2D numerical molecular descriptors calculated from 3D interaction energy grid maps) or physicochemical and structural descriptors (e.g. log D, H-bond donors, ionisation potential) (Doddareddy et al. 2006; Manga et al. 2003; Dave and Morris 2015). The rate of renal clearance was predicted using *in silico*

models developed with different statistical tools such as Partial Least Squares (PLS) and Random Forests (RF) based on a human renal clearance data set of 349 drugs with active secretion and net re-absorption (Paine et al. 2010).

A mechanistic kidney model has been developed based on various physiological and anatomical parameters (e.g. nephron size and number, number of proximal tubular cells per gram of kidney, flow rates of tubular fluid and urine and pH values in tubular cells/fluid) and is incorporated in the SimCyp® simulator (Certara, Sheffield, UK) (Jamei et al. 2009). In this model the nephron is divided into eight segments with three compartments (tubular fluid, cell mass and blood space). The processes integrated in the model include passive permeability across basal and apical membranes of each cell compartment, uptake and efflux transport across the basal and apical membranes of each proximal tubular cell compartment, metabolic clearance in proximal tubular cell compartments and bypass of a fraction of the renal blood flow (no passage through glomerulus, the Loop of Henle and subsequent segments) (Neuhoff et al. 2013). The input needed in terms of drug properties are information about drug binding and ionisation, passive permeability and transporter kinetics. The advantage of such a mechanistic model is that interindividual variability (demographics, gender, disease) can be integrated.

## 6. Physiologically-based pharmacokinetic models

The various previously presented *in vitro* and *in silico* ADME tools can be used separately to consider each of the ADME parameters. Linking the information from the different *in vitro* assays and *in silico* predictions offers the opportunity to predict *in vivo* performance, such as plasma concentration profiles, drug concentrations in specific compartments of the body and to investigate Drug-Drug interactions. PBPK models were built for this purpose and consider the processes of absorption, distribution, metabolism and excretion of a drug mechanistically (Figure 13.3).

Please insert Figure 13.3 here

For drug absorption, the complex compartmental absorption transit models (as described above in Section 2.2.6) are used in PBPK models together with information about various physiological parameters such as gastrointestinal transit times, luminal fluid volumes, luminal fluid pHs, regional differences in enzyme/transporter density and surface area of the gastrointestinal tract (Jamei et al. 2009). Drug release from different pharmaceutical formulation types such as

controlled or modified release systems, enteric-coated granules or tablets and suspensions can also be considered.

Regarding drug distribution, PBPK models consider the whole body using predicted tissue:partition coefficients (as described above in Section 3.2) and literature data from physiological parameters such as body and organ size, blood flow rates, tissue and blood composition. Tissues include for example bone, brain, gut, heart, kidney, liver, lung, pancreas, muscle, skin, spleen and adipose tissue which are usually defined as perfusion-limited tissues. A modification to permeability-limited tissues and integration of active transporter processes using experimental data of transport kinetics is possible. This mechanistic approach allows tracking of the drug concentration in a specific tissue. If such a complex distribution model is not needed, simple compartmental or minimal pharmacokinetic models can be used.

Metabolism and excretion can be integrated at the enzymatic level (metabolizing enzymes and transporters) in the metabolizing and/or eliminating organs which can be considered as perfusion- or permeability-limited tissues (Kostewicz et al. 2014a). For metabolizing enzymes or transporters, the input data required includes *in vitro* information about enzyme kinetics (e.g.,  $V_{\max}$  and  $k_m$ ) which is scaled to the whole organ with literature information about enzymatic expression in specific organs and organ size. It is also possible to use other *in vitro* approaches such as hepatocytes with appropriate scaling factors as described above in Section 4.2.

Apart from physiological data based on the population, additional input data includes drug-dependent parameters, formulation-dependent parameters and information about the design of the virtual trial. For several drug-dependent parameters, it is also possible to use *in silico* predictions as input information instead of experimental data (e.g., logP, permeability, PPB, RBC partitioning, aqueous and bile micelle mediated solubility) (Fotaki 2009). As more *in vitro*, preclinical or clinical data becomes available in the drug discovery process, these data can be used to refine the existing model. PBPK models can also be coupled with pharmacodynamic models to study the relevance of pharmacokinetic changes on therapeutic effects. In recent years, PBPK models were constantly improved by integrating more physiological processes, increasing the mechanistic background of the model and updating physiological information with newly available literature data such as gastrointestinal transit times, demographics and expression of transporters and metabolizing enzymes (Rostami-Hodjegan 2012). A main advantage of PBPK models is the integration of population variability in the model to investigate drug product performance in populations that are not usually represented in clinical trials. For example, in the SimCyp® simulator (Certara, Sheffield, UK), default populations

include different disease states (obesity, liver cirrhosis, renal impairment, rheumatoid arthritis), ethnicities (Chinese, Japanese, Caucasian), pregnancy and age groups (paediatric, geriatric) (Jamei et al. 2009).

## 7. Conclusion

Many interrelated processes contribute to determining the pharmacokinetic profile of a drug. A variety of useful *in vitro* and *in silico* methods to predict single ADME parameters is available to predict specific processes. The choice of the *in vitro* and *in silico* method depends on the drug discovery stage, the drug properties and the available compound data. Current approaches aim to integrate available *in silico* tools and experimental data from *in vitro* assays to predict drug plasma profiles using PBPK modeling. With the integration of physiological data from different populations in PBPK models, it is also possible to predict pharmacokinetics in special populations and to estimate interindividual variability. All these tools contribute to the reduction of drug attrition rate in later stages of drug development, to the minimization of time and costs in drug development and to the reduction of clinical studies. Further advancements are expected when PBPK models are set up in very early stages of drug development and confidence in the model grows by further integrating *in vitro*, *preclinical* and *clinical* data as it becomes available.

## Acknowledgements

This work has received funding from Horizon 2020 Marie Skłodowska-Curie Innovative Training Networks programme under grant agreement No. 674909 (PEARRL).

## References

- Abraham MH, Grellier PL, McGill RA (1987) Determination of olive oil–gas and hexadecane–gas partition coefficients, and calculation of the corresponding olive oil–water and hexadecane–water partition coefficients. *J Chem Soc, Perkin Trans 2* (6):797-803.  
doi:10.1039/p29870000797
- Alqahtani S, Mohamed LA, Kaddoumi A (2013) Experimental models for predicting drug absorption and metabolism. *Expert Opin Drug*

- Metab Toxicol 9 (10):1241-1254.  
doi:10.1517/17425255.2013.802772
- Amidon GL, Lennernas H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharm Res* 12 (3):413-420
- Andrade CH, Silva DC, Braga RC (2014) In silico prediction of drug metabolism by P450. *Curr Drug Metab* 15 (5):514-525
- Avdeef A (2012) *Permeability: Caco-2/MDCK*. Hoboken, NJ, USA: John Wiley & Sons, Inc., Hoboken, NJ, USA.  
doi:10.1002/9781118286067.ch8
- Baker RW (1987) *Controlled release of biologically active agents*. John Wiley & Sons, New York
- Ballard P, Leahy DE, Rowland M (2003) Prediction of in vivo tissue distribution from in vitro data. 2. Correlation between in vitro and in vivo tissue distribution of a homologous series of nine 5-n-alkyl-5-ethyl barbituric acids. *Pharm Res* 20 (6):864-872.  
doi:10.1023/A:1023912318133
- Berezhkovskiy LM (2004) Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. *J Pharm Sci* 93 (6):1628-1640. doi:10.1002/jps.20073
- Bergstrom CA, Holm R, Jorgensen SA, Andersson SB, Artursson P, Beato S, Borde A, Box K, Brewster M, Dressman J, Feng KI, Halbert G, Kostewicz E, McAllister M, Muenster U, Thinnis J, Taylor R, Mullertz A (2014) Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. *Eur J Pharm Sci* 57:173-199. doi:10.1016/j.ejps.2013.10.015
- Bohets H, Annaert P, Mannens G, Van Beijsterveldt L, Anciaux K, Verboven P, Meuldermans W, Lavrijsen K (2001) Strategies for absorption screening in drug discovery and development. *Curr Top Med Chem* 1 (5):367-383. doi:10.2174/1568026013394886
- Boni JE, Brickl RS, Dressman J (2007) Is bicarbonate buffer suitable as a dissolution medium? *J Pharm Pharmacol* 59 (10):1375-1382.  
doi:10.1211/jpp.59.10.0007
- Braun A, Hammerle S, Suda K, Rothen-Rutishauser B, Gunthert M, Kramer SD, Wunderli-Allenspach H (2000) Cell cultures as tools in biopharmacy. *Eur J Pharm Sci* 11 Suppl 2:S51-60

- Broccatelli F, Salphati L, Plise E, Cheong J, Gobbi A, Lee ML, Aliagas I (2016) Predicting Passive Permeability of Drug-like Molecules from Chemical Structure: Where Are We? *Mol Pharm* 13 (12):4199-4208. doi:10.1021/acs.molpharmaceut.6b00836
- Bröer S (2010) *Xenopus laevis* Oocytes. In: Yan Q (ed) *Membrane Transporters in Drug Discovery and Development: Methods and Protocols*. Humana Press, Totowa, NJ, pp 295-310. doi:10.1007/978-1-60761-700-6\_16
- Brunner E (1904) Reaktionsgeschwindigkeit in heterogenen Systemen. *Zeitschrift für Physikalische Chemie*, vol 47U. doi:10.1515/zpch-1904-4705
- Caldwell GW, Yan Z (2014) *Optimization in Drug Discovery: In Vitro Methods*. 2 edn. Humana Press, Springer, New York
- Carbinatto FM, de Castro AD, Evangelista RC, Cury BSF (2014) Insights into the swelling process and drug release mechanisms from cross-linked pectin/high amylose starch matrices. *Asian Journal of Pharmaceutical Sciences* 9 (1):27-34. doi:10.1016/j.ajps.2013.12.002
- Chang C, Swaan PW (2006) Computational approaches to modeling drug transporters. *Eur J Pharm Sci* 27 (5):411-424. doi:10.1016/j.ejps.2005.09.013
- Chen Y, Cameron K, Guzman-Perez A, Perry D, Li D, Gao H (2010) Structure-pharmacokinetic relationship of in vivo rat biliary excretion. *Biopharm Drug Dispos* 31 (1):82-90. doi:10.1002/bdd.692
- Dave RA, Morris ME (2015) Quantitative structure-pharmacokinetic relationships for the prediction of renal clearance in humans. *Drug Metab Dispos* 43 (1):73-81. doi:10.1124/dmd.114.059857
- de Groot MJ (2006) Designing better drugs: predicting cytochrome P450 metabolism. *Drug Discov Today* 11 (13-14):601-606. doi:10.1016/j.drudis.2006.05.001
- Di L, Fish PV, Mano T (2012a) Bridging solubility between drug discovery and development. *Drug Discov Today* 17 (9-10):486-495. doi:10.1016/j.drudis.2011.11.007
- Di L, Keefer C, Scott DO, Strelevitz TJ, Chang G, Bi YA, Lai Y, Duckworth J, Fenner K, Troutman MD, Obach RS (2012b) Mechanistic insights from comparing intrinsic clearance values between human liver



- microsomes and hepatocytes to guide drug design. *Eur J Med Chem* 57:441-448. doi:10.1016/j.ejmech.2012.06.043
- Di L, Kerns EH, Carter GT (2009) Drug-like property concepts in pharmaceutical design. *Curr Pharm Des* 15 (19):2184-2194
- Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, Lai Y, Federico JJ, 3rd, Davidson RE, Smith R, Reyner EL, Lee C, Feng B, Rotter C, Varma MV, Kempshall S, Fenner K, El-Kattan AF, Liston TE, Troutman MD (2011) Development of a new permeability assay using low-efflux MDCKII cells. *J Pharm Sci* 100 (11):4974-4985. doi:10.1002/jps.22674
- Doddareddy MR, Cho YS, Koh HY, Kim DH, Pae AN (2006) In silico renal clearance model using classical Volsurf approach. *J Chem Inf Model* 46 (3):1312-1320. doi:10.1021/ci0503309
- Dokoumetzidis A, Kalantzi L, Fotaki N (2007) Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. *Expert Opin Drug Metab Toxicol* 3 (4):491-505. doi:10.1517/17425225.3.4.491
- Dressman JB, Amidon GL, Reppas C, Shah VP (1998) Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms. *Pharmaceutical research* 15 (1):11-22. doi:10.1023/a:1011984216775
- Dressman JB, Fleisher D (1986) Mixing-tank model for predicting dissolution rate control or oral absorption. *J Pharm Sci* 75 (2):109-116
- Elaut G, Papeleu P, Vinken M, Henkens T, Snykers S, Vanhaecke T, Rogiers V (2006) Hepatocytes in suspension. *Methods Mol Biol* 320:255-263. doi:10.1385/1-59259-998-2:255
- Fotaki N (2009) Pros and cons of methods used for the prediction of oral drug absorption. *Expert Rev Clin Pharmacol* 2 (2):195-208. doi:10.1586/17512433.2.2.195
- Fotaki N (2011) Flow-Through Cell Apparatus (USP Apparatus 4): Operation and Features. *Dissolution Technologies* 18:46-49. doi:10.14227/DT180411P46
- Fotaki N, Vertzoni M (2010) Biorelevant dissolution methods and their applications in in vitro in vivo correlations for oral formulations. *The Open Drug Delivery Journal* 4 (1):2-13. doi:10.2174/1874126601004010002

- Galia E, Nicolaidis E, Horter D, Lobenberg R, Reppas C, Dressman JB (1998) Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. *Pharm Res* 15 (5):698-705
- Ghibellini G, Leslie EM, Brouwer KL (2006) Methods to evaluate biliary excretion of drugs in humans: an updated review. *Mol Pharm* 3 (3):198-211. doi:10.1021/mp060011k
- Hansen NT, Kouskoumvekaki I, Jorgensen FS, Brunak S, Jonsdottir SO (2006) Prediction of pH-dependent aqueous solubility of druglike molecules. *J Chem Inf Model* 46 (6):2601-2609. doi:10.1021/ci600292q
- Hayduk W, Laudie H (1974) Prediction of Diffusion-Coefficients for Nonelectrolytes in Dilute Aqueous-Solutions. *Aiche Journal* 20 (3):611-615. doi:10.1002/aic.690200329
- Heikkinen AT, Baneyx G, Caruso A, Parrott N (2012) Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus. *Eur J Pharm Sci* 47 (2):375-386. doi:10.1016/j.ejps.2012.06.013
- Higuchi T (1961) Rate of release of medicaments from ointment bases containing drugs in suspension. *J Pharm Sci* 50:874-875
- Hill AP, Young RJ (2010) Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. *Drug Discov Today* 15 (15-16):648-655. doi:10.1016/j.drudis.2010.05.016
- Hinderling PH (1984) Kinetics of partitioning and binding of digoxin and its analogues in the subcompartments of blood. *J Pharm Sci* 73 (8):1042-1053
- Hintz RJ, Johnson KC (1989) The effect of particle size distribution on dissolution rate and oral absorption. *International Journal of Pharmaceutics* 51 (1):9-17. doi:10.1016/0378-5173(89)90069-0
- Hixson AW, Crowell JH (1931) Dependence of Reaction Velocity upon surface and Agitation. *Industrial & Engineering Chemistry* 23 (8):923-931. doi:10.1021/ie50260a018
- Jain N, Yalkowsky SH (2001) Estimation of the aqueous solubility I: application to organic nonelectrolytes. *J Pharm Sci* 90 (2):234-252. doi:10.1002/1520-6017(200102)90:2<234::AID-JPS14>3.0.CO;2-V
- Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A (2009) The Simcyp® Population-based ADME Simulator. *Expert*

- Opin Drug Metab Toxicol 5 (2):211-223.  
doi:10.1517/17425250802691074
- Kennedy T (1997) Managing the drug discovery/development interface. Drug Discovery Today 2 (10):436-444. doi:10.1016/S1359-6446(97)01099-4
- Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 (8):711-715. doi:10.1038/nrd1470
- Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, Jamei M, Lloyd R, Pepin X, Rostami-Hodjegan A, Sjogren E, Tannergren C, Turner DB, Wagner C, Weitschies W, Dressman J (2014a) PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci 57:300-321. doi:10.1016/j.ejps.2013.09.008
- Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, Dickinson PA, Dressman J, Holm R, Klein S, Mann J, McAllister M, Minekus M, Muenster U, Mullertz A, Verwei M, Vertzoni M, Weitschies W, Augustijns P (2014b) In vitro models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci 57:342-366. doi:10.1016/j.ejps.2013.08.024
- Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB (2004) Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol 56 (1):43-51. doi:10.1211/0022357022511
- Kuentz M (2008) Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J 10 (3):473-479. doi:10.1208/s12248-008-9054-3
- Kunze A, Huwyler J, Poller B, Gutmann H, Camenisch G (2014) In vitro-in vivo extrapolation method to predict human renal clearance of drugs. J Pharm Sci 103 (3):994-1001. doi:10.1002/jps.23851
- Kuteykin-Teplyakov K, Luna-Tortos C, Ambroziak K, Loscher W (2010) Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J Pharmacol 160 (6):1453-1463. doi:10.1111/j.1476-5381.2010.00801.x
- Lambrinidis G, Vallianatou T, Tsantili-Kakoulidou A (2015) In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review. Adv Drug Deliv Rev 86:27-45. doi:10.1016/j.addr.2015.03.011

- Langenbucher F (1972) Linearization of dissolution rate curves by the Weibull distribution. *J Pharm Pharmacol* 24 (12):979-981
- Lave T, Chapman K, Goldsmith P, Rowland M (2009) Human clearance prediction: shifting the paradigm. *Expert Opin Drug Metab Toxicol* 5 (9):1039-1048. doi:10.1517/17425250903099649
- Lea T (2015) Caco-2 Cell Line. In: Verhoeckx K, Cotter P, López-Expósito I et al. (eds) *The Impact of Food Bioactives on Health: in vitro and ex vivo models*. Springer International Publishing, Cham, pp 103-111. doi:10.1007/978-3-319-16104-4\_10
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1PII of original article: S0169-409X(96)00423-1. The article was originally published in *Advanced Drug Delivery Reviews* 23 (1997) 3–25.1. *Advanced Drug Delivery Reviews* 46 (1):3-26. doi:10.1016/S0169-409X(00)00129-0
- Liu F, Merchant HA, Kulkarni RP, Alkademi M, Basit AW (2011) Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products. *Eur J Pharm Biopharm* 78 (1):151-157. doi:10.1016/j.ejpb.2011.01.001
- Luo G, Johnson S, Hsueh MM, Zheng J, Cai H, Xin B, Chong S, He K, Harper TW (2010) In silico prediction of biliary excretion of drugs in rats based on physicochemical properties. *Drug Metab Dispos* 38 (3):422-430. doi:10.1124/dmd.108.026260
- Mahmood I (1998) Interspecies scaling of renally secreted drugs. *Life Sci* 63 (26):2365-2371
- Manga Nn, Duffy JC, Rowe PH, Cronin MTD (2003) A Hierarchical QSAR Model for Urinary Excretion of Drugs in Humans as a Predictive Tool for Biotransformation. *QSAR & Combinatorial Science* 22 (2):263-273. doi:10.1002/qsar.200390021
- Markopoulos C, Andreas CJ, Vertzoni M, Dressman J, Reppas C (2015) In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media. *Eur J Pharm Biopharm* 93:173-182. doi:10.1016/j.ejpb.2015.03.009
- Martin YC (2005) A bioavailability score. *J Med Chem* 48 (9):3164-3170. doi:10.1021/jm0492002

- Mithani SD, Bakatselou V, TenHoor CN, Dressman JB (1996) Estimation of the increase in solubility of drugs as a function of bile salt concentration. *Pharm Res* 13 (1):163-167
- Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM (2013) Renal transporters in drug development. *Annu Rev Pharmacol Toxicol* 53:503-529. doi:10.1146/annurev-pharmtox-011112-140317
- Muegge I, Heald SL, Brittelli D (2001) Simple selection criteria for drug-like chemical matter. *J Med Chem* 44 (12):1841-1846
- Nernst W (1904) Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen. *Zeitschrift für Physikalische Chemie* 47 (1). doi:10.1515/zpch-1904-4704
- Neuhoff S, Gaohua L, Burt H, Jamei M, Li L, Tucker GT, Rostami-Hodjegan A (2013) Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM). In: Sugiyama Y, Steffansen B (eds) *Transporters in Drug Development: Discovery, Optimization, Clinical Study and Regulation*. Springer New York, New York, NY, pp 155-177. doi:10.1007/978-1-4614-8229-1\_7
- Ni PF, Ho NFH, Fox JL, Leuenberger H, Higuchi WI (1980) Theoretical model studies of intestinal drug absorption V. Non-steady-state fluid flow and absorption. *Int J Pharm* 5 (1):33-47. doi:10.1016/0378-5173(80)90048-4
- Niederquell A, Kuentz M (2018) Biorelevant Drug Solubility Enhancement Modeled by a Linear Solvation Energy Relationship. *J Pharm Sci* 107 (1):503-506. doi:10.1016/j.xphs.2017.08.017
- Noyes AA, Whitney WR (1897) The Rate of Solution of Solid Substances in Their Own Solutions. *Journal of the American Chemical Society* 19 (12):930-934. doi:10.1021/ja02086a003
- Paine SW, Barton P, Bird J, Denton R, Menochet K, Smith A, Tomkinson NP, Chohan KK (2010) A rapid computational filter for predicting the rate of human renal clearance. *J Mol Graph Model* 29 (4):529-537. doi:10.1016/j.jmgm.2010.10.003
- Paine SW, Menochet K, Denton R, McGinnity DF, Riley RJ (2011) Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. *Drug Metab Dispos* 39 (6):1008-1013. doi:10.1124/dmd.110.037267
- Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube"

- model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. *J Pharmacokinet Biopharm* 5 (6):625-653. doi:10.1007/bf01059688
- Peters SA (2012) Physiologically-based pharmacokinetic (PBPK) modeling and simulations. John Wiley & Sons, Inc., Hoboken, New Jersey
- Poulin P, Theil FP (2000) A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. *J Pharm Sci* 89 (1):16-35. doi:10.1002/(sici)1520-6017(200001)89:1<16::aid-jps3>3.0.co;2-e
- Poulin P, Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. *J Pharm Sci* 91 (1):129-156
- Richardson SJ, Bai A, Kulkarni AA, Moghaddam MF (2016) Efficiency in Drug Discovery: Liver S9 Fraction Assay As a Screen for Metabolic Stability. *Drug Metabolism Letters* 10 (2):83-90. doi:10.2174/1872312810666160223121836
- Rodgers T, Leahy D, Rowland M (2005a) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. *J Pharm Sci* 94 (6):1259-1276. doi:10.1002/jps.20322
- Rodgers T, Leahy D, Rowland M (2005b) Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. *J Pharm Sci* 94 (6):1237-1248. doi:10.1002/jps.20323
- Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. *J Pharm Sci* 95 (6):1238-1257. doi:10.1002/jps.20502
- Rodgers T, Rowland M (2007) Mechanistic approaches to volume of distribution predictions: understanding the processes. *Pharm Res* 24 (5):918-933. doi:10.1007/s11095-006-9210-3
- Rostami-Hodjegan A (2012) Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. *Clin Pharmacol Ther* 92 (1):50-61. doi:10.1038/clpt.2012.65

- Scotcher D, Jones C, Posada M, Rostami-Hodjegan A, Galetin A (2016a) Key to Opening Kidney for In Vitro–In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data. *AAPS J* 18 (5):1067-1081. doi:10.1208/s12248-016-9942-x
- Scotcher D, Jones C, Rostami-Hodjegan A, Galetin A (2016b) Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. *Eur J Pharm Sci* 94:59-71. doi:10.1016/j.ejps.2016.03.018
- Sharifi M, Ghafourian T (2014) Estimation of biliary excretion of foreign compounds using properties of molecular structure. *AAPS J* 16 (1):65-78. doi:10.1208/s12248-013-9541-z
- Siepmann J, Peppas NA (2011) Higuchi equation: derivation, applications, use and misuse. *Int J Pharm* 418 (1):6-12. doi:10.1016/j.ijpharm.2011.03.051
- Stappaerts J, Brouwers J, Annaert P, Augustijns P (2015) In situ perfusion in rodents to explore intestinal drug absorption: challenges and opportunities. *Int J Pharm* 478 (2):665-681. doi:10.1016/j.ijpharm.2014.11.035
- Sugano K (2012) *Biopharmaceutics Modeling and Simulations: Theory, Practice, Methods, and Applications*. Hoboken, NJ, USA: John Wiley & Sons, Inc., Hoboken, NJ, USA. doi:10.1002/9781118354339
- Swift B, Pfeifer ND, Brouwer KL (2010) Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. *Drug Metab Rev* 42 (3):446-471. doi:10.3109/03602530903491881
- Takada T, Suzuki H, Sugiyama Y (2005) Characterization of polarized expression of point- or deletion-mutated human BCRP/ABCG2 in LLC-PK1 cells. *Pharm Res* 22 (3):458-464. doi:10.1007/s11095-004-1884-9
- Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, Yamashita S (2006) Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. *Pharm Res* 23 (6):1144-1156. doi:10.1007/s11095-006-0162-4
- US Pharmacopeial Convention (2005) USP 29, NF 24: the United States Pharmacopeia, the National Formulary. 711 Dissolution.

- van de Kerkhof EG, de Graaf IA, Groothuis GM (2007) In vitro methods to study intestinal drug metabolism. *Curr Drug Metab* 8 (7):658-675
- van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? *Nat Rev Drug Discov* 2 (3):192-204. doi:10.1038/nrd1032
- Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. *J Med Chem* 45 (12):2615-2623
- Wang J, Flanagan DR (1999) General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. *J Pharm Sci* 88 (7):731-738. doi:10.1021/js980236p
- Wang J, Flanagan DR (2002) General solution for diffusion-controlled dissolution of spherical particles. 2. Evaluation of experimental data. *J Pharm Sci* 91 (2):534-542. doi:10.1002/jps.10039
- Wang QX, Fotaki N, Mao Y (2009) Biorelevant Dissolution: Methodology and Application in Drug Development. *Dissolution Technologies* 16 (3):6-12. doi:10.14227/Dt160309p6
- Watanabe T, Kusuhara H, Watanabe T, Debori Y, Maeda K, Kondo T, Nakayama H, Horita S, Ogilvie BW, Parkinson A, Hu Z, Sugiyama Y (2011) Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. *Drug Metab Dispos* 39 (6):1031-1038. doi:10.1124/dmd.110.036129
- Westhouse RA, Car BD (2007) Chapter 9 - Concepts in Pharmacology and Toxicology. In: Prendergast GC, Jaffee EM (eds) *Cancer Immunotherapy*. Academic Press, Burlington, pp 149-166. doi:10.1016/B978-012372551-6/50073-0
- Willmann S, Schmitt W, Keldenich J, Dressman JB (2003) A physiologic model for simulating gastrointestinal flow and drug absorption in rats. *Pharm Res* 20 (11):1766-1771
- Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB (2004) A physiological model for the estimation of the fraction dose absorbed in humans. *J Med Chem* 47 (16):4022-4031. doi:10.1021/jm030999b
- Willmann S, Thelen K, Lippert J (2012) Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®. *J*



Pharm Pharmacol 64 (7):997-1007. doi:10.1111/j.2042-7158.2012.01534.x

Yang J, Jamei M, Yeo K, Tucker G, Rostami-hodjegan A (2007) Prediction of Intestinal First-Pass Drug Metabolism. *Curr Drug Metab* 8 (7):676-684. doi:10.2174/138920007782109733

Yu LX, Amidon GL (1999) A compartmental absorption and transit model for estimating oral drug absorption. *Int J Pharm* 186 (2):119-125. doi:10.1016/S0378-5173(99)00147-7

Yu LX, Lipka E, Crison JR, Amidon GL (1996) Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. *Adv Drug Deliv Rev* 19 (3):359-376

Zhang X, Shedden K, Rosania GR (2006) A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. *Mol Pharm* 3 (6):704-716. doi:10.1021/mp060046k

## List of tables

Table 13.1: Overview of different in vitro permeability assays (Alqahtani et al. 2013; Caldwell and Yan 2014)

| Permeability assay | PAMPA  | Caco-2  | MDCK   | Ussing chamber  | <i>In situ</i> perfusion studies  |
|--------------------|--|---|--|---|---|
| <b>Advantages</b>  | <ul style="list-style-type: none"> <li>• ↓Costs</li> <li>• ↓Experimental time</li> <li>• Suitable for High Throughput Screening</li> </ul> | <ul style="list-style-type: none"> <li>• Human cell lines with tight junctions, enzyme transporters, P-gp and multi-drug resistance proteins, some CYP450 isoenzymes and Phase 2 enzymes</li> </ul> | <ul style="list-style-type: none"> <li>• ↓Time needed for cells to form a polarised monolayer with well-established tight junctions</li> </ul> | <ul style="list-style-type: none"> <li>• Good prediction of intestinal drug absorption</li> <li>• Influx/efflux transport</li> <li>• Drug metabolism</li> </ul> | <ul style="list-style-type: none"> <li>• Assessment of regional intestinal differences</li> <li>• Assessment of intestinal drug transport and metabolism</li> <li>• Assessment of dose-dependent</li> </ul> |

|                      |  |   |  |  |  |
|----------------------|--|---|--|--|--|
|                      |  | <ul style="list-style-type: none"> <li>• Suitable for High Throughput Screening</li> </ul>  | <ul style="list-style-type: none"> <li>• (3-5 days)<br/>↓TEER values</li> </ul>  |  | pharmacokinetics   |
| <b>Disadvantages</b> | <ul style="list-style-type: none"> <li>• Considers only passive transcellular permeability of compounds</li> </ul> | <ul style="list-style-type: none"> <li>• Long time (ca. 21 days) to form tight junctions/express higher amount of efflux transporters</li> <li>• Wide variation with passage number</li> <li>• ↑ Variability between laboratories</li> <li>• Underestimation of paracellular transport → "tighter" tight junctions compared to <i>in vivo</i> situation</li> <li>• ↓ Expression of CYP3A enzymes</li> </ul> | <ul style="list-style-type: none"> <li>• Canine origin (but transfection with P-gp, MRPs, BCRP is possible)</li> </ul> | <ul style="list-style-type: none"> <li>• Can only be used for 2-3 h due to tissue viability</li> </ul> | <ul style="list-style-type: none"> <li>• Effect of anaesthesia</li> <li>• Not practical for high throughput screening</li> <li>• Overestimation of absorption for drugs with gut wall metabolism or accumulation in gut wall possible</li> </ul> |

Figure captions

|                  | Level 0 | Level 1         | Level 2   | Level 3                   |
|------------------|---------|-----------------|---|---------------------------|
| Media properties | pH      | Buffer capacity | Osmolality  | Viscosity                 |
| Media components |         |                 | Bile components, dietary lipids, lipid digestion products | Dietary proteins, enzymes |

Figure 13.1: Levels of biorelevant media recommended for the simulation of human gastrointestinal fluids during oral formulation development (modified from Markopoulos et al. (2015))




Figure 13.2: Various types of molecular descriptors used for *in silico* prediction of ADME parameters (modified from Dokoumetzidis et al. (2007))




Figure 13.3: Description of basic elements of physiologically based pharmacokinetic modeling (PO: per os, IV: intravenous)

